NCAM1 and cancer: Increased percentages of CD56+CD16dim/neg NK cells in the peripheral blood of some patients with these cancers suggest phenotype-altering effects can extend beyond the local tumor environment and may be indicative of disease progression and metastasis [2, 26–28].